Stock 000963 HUADONG MEDICINE CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Huadong Medicine Co., Ltd

Equities

000963

CNE0000011S1

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
32.99 CNY +3.68% Intraday chart for Huadong Medicine Co., Ltd +11.83% -20.43%
Apr. 18 Huadong Medicine's 2023 Profit Jumps 14% MT
Apr. 17 Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Huadong Medicine's 2023 Profit Jumps 14%
MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China's first biosimilar Ozempic drug applies for approval
RE
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center
MT
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center
MT
Huadong Medicine's 2023 Profit to Climb Up to 14.5%
MT
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan
MT
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution
MT
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.
CI
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm
CI
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%
MT
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora Cream in Greater China
AQ
Huadong Medicine Enters Exclusive Licensing Agreement with Denmark’s MC2
MT
CARsgen Announced 2023 Interim Results
AQ
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts
MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Huadong Medicine Buys Rights to US Skincare Drug For $100 Million
MT
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
AQ
Arcutis Authorizes Huadong Medicine Unit to Manufacture, Commercialize Topical Roflumilast in China, Southeast Asia
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 000963 Stock
  4. News Huadong Medicine Co., Ltd